Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese coronary artery disease (JCAD) study

Circulation Journal

Volumn 74, Issue 3, 2010, Pages 503-509

  Horinaka, Shigeo ^a   Yabe, Akihisa ^a   Yagi, Hiroshi ^a   Ishimitsu, Toshihiko ^a   Yamazaki, Tsutomu ^b   Suzuki, Shinya ^b   Kohro, Takahide ^b   Nagai, Ryozo ^c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cardiovascular events; Coronary artery disease; Japanese coronary artery disease (JCAD) study; Nicorandil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; SULFONYLUREA;

ADULT; AGED; ARTICLE; BRAIN DEATH; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NICORANDIL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77649196143     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0649     Document Type: Article

References (31)

1. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18J-24J.
2. Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by Nicorandil (SG-75). J Cardiovasc Pharmacol 1983; 5: 364-370.
3. Grover GJ. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 1997; 75: 309-315.
4. Ohno Y, Minatoguchi S, Uno Y, Kariya T, Arai M, Yamashita K, et al. Nicorandil reduces myocardial infarct size by opening the KATP channel in rabbits. Int J Cardiol 1997; 62: 181-190.
5. Schultz JE, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol 1997; 272: H2607-H2615.
6. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction: A meta-analysis. Circ J 2009; 73: 925-931.
7. Lee HC, An SG, Choi JH, Lee TK, Kim J, Kim JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J 2008; 72: 1425-1429.
8. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002; 359: 1269-1275.
9. The Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan: The Japanese Coronary Artery Disease Study (The JCAD Study). Circ J 2006; 70: 1256-1262.
10. Kambara H, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R, et al. Gender differences in patients with coronary artery disease in Japan: The Japanese Coronary Artery Disease Study (the JCAD study). Circ J 2009; 73: 912-917.
11. Okura T, Higaki J, Kurata M, Irita J, Miyoshi K, Yamazaki T, et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J 2009; 73: 885-891.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
13. Chambless L, Keil U, Dobson A, Mähönen M, Kuulasmaa K, Rajakangas AM, et al. Population versus clinical view of case fatality from acute coronary heart disease: Results from the WHO MONICA Project 1985-1990: Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation 1997; 96: 3849-3859.
14. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe: Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-1248.
15. IONA Study Group. Impact of nicorandil in angina: Subgroup analyses. Heart 2004; 90: 1427-1430.
16. Miura T, Liu Y, Kita H, Ogawa T, Shimamoto K. Roles of mitochondria ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 2000; 35: 238-245.
17. Fukuda H, Luo CS, Guo LL Digerness SB, Li J, Pike MM. The effect of KATP channel activation on myocardial cationic and energetic status during ischemia and reperfusion: Role in cardioprotection. J Mol Cell Cardiol 2001; 33: 545-560.
18. Maczewski M, Bercewicz A. The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts. J Mol Cell Cardiol 1998; 30: 1735-1747.
19. Ren Z, Yang Q, Floten HS, Furnary AP, Yim AP, He GW. ATP-sensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. Ann Thorac Surg 2001; 71: 642-647.
20. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina: Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J 1999; 20: 51-57.
21. Simpson D, Wellington K. Nicorandil: A review of its use in the management of stable angina pectoris, including high risk patients. Drugs 2004; 64: 1941-1955.
22. Kato T, Kamiyama T, Maruyama Y, Tanaka S, Yoshimoto N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J 2001; 141: 940-943.
23. Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, et al. Efficacy of oral nicorandil in patients with end-stage renal disease: A retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 2007; 29: 110-122.
24. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effect of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46: 63-67.
25. Kasama S, Toyama T, Hatori T, Kumakura H, Takayama Y, Ichikawa S, et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005; 150: 477.e1-477.e8.
26. Sanada S, Node K, Asanuma H, Ogita H, Takashima S, Minamino T, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: Role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J Am Coll Cardiol 2002; 40: 991-997.
27. Horinaka S, Kobayashi N, Yagi H, Mori Y, Matsuoka H. Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertension rats with congestive heart failure. J Cardiovasc Pharmacol 2006; 47: 629-635.
28. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, J-WIND investigators, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomized trials. Lancet 2007; 370: 1483-1493.
29. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic KATP channel to gliclazide. Diabetologia 1999; 42: 845-848.
30. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 311-316.
31. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537.